Switzerland· 66577002
Steglatro 5 mg, Filmtabletten
A ertugliflozin product containing ertugliflozinum, registered in Switzerland by MSD Merck Sharp & Dohme AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ertugliflozin is registered in 11 of 19 countries.
Countries holding a registration under ATC A10BK04 (ertugliflozin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Ertugliflozin · ATC A10BK04
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of ertugliflozin costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $2.89 in Italy to $4.50 in Switzerland — a ×1.6 gap.
- Switzerland: $4.50 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ertugliflozin · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$4.50
- IT Italy$2.89
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ertugliflozinum
- Manufacturer
- MSD Merck Sharp & Dohme AG
- Country
- Switzerland (CH)
- ATC code
- A10BK04
- ATC class
- Ertugliflozin
- Defined daily dose
- 10 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680665770024Blist 98 StkCHF 162.55
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
417 interactions on record for ertugliflozin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ertugliflozin · interactions on record
417 records
- 1 severe
- 376 moderate
- 40 minor
Most severe, free to view
- SucralfateA02BX02moderate
- PapaverineA03AD01moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ertugliflozin in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSTEGLATROMerck Sharp & Dohme B.V., Haarlem
- SpainSTEGLATRO 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- PolandSteglatroMerck Sharp & Dohme B.V.
- SwedenSteglatro 5 mg Filmdragerad tablettMerck Sharp & Dohme BV
- United StatesSTEGLATROMerck Sharp & Dohme LLC
- IcelandSteglatroMerck Sharp & Dohme B.V.*
- United KingdomSteglatro 15mg tabletsMerck Sharp & Dohme (UK) Ltd
- ItalySTEGLATRO*28 cpr rivestite 15 mgMERCK SHARP & DOHME BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Steglatro
- Liechtenstein · Steglatro
- Norway · Steglatro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/532dde62-b765-4186-b22b-713fc1340f5d GET /v1/drugs/532dde62-b765-4186-b22b-713fc1340f5d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ertugliflozinum 5 mg",
"valid_from": "2019-01-01",
"limitations": "[{\"description\":\"Zur Behandlung von Patienten mit einem Typ 2 Diabetes mellitus zur Verbesserung der glykämischen Kontrolle, wenn durch Diät und gesteigerte körperliche Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird:<br>\\n- Als Monotherapie, bei Patienten, die nicht mit Metformin behandelt werden können.<br>\\n- In Kombination mit den blutzuckersenkenden Arzneimitteln Metformin, DPP4-Inhibitoren mit oder ohne Metformin oder Sulfonylharnstoffen, wenn diese Behandlung keine ausreichende glykämische Kontrolle ermöglicht.<br>\\nEs wird maximal eine Tagesdosierung von 5 mg Ertugliflozin vergütet.<br>\\n<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-12-01\"}]",
"galenic_form": "Filmtabl 5 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2019-01-01",
"self_retention_pct": 10
}See everything about ertugliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.